AR and prostate cancer: Effectiveness of particular inhibitors in vivo and in vitro has been shown in double-negative prostate cancer models, and these tumors usually display active FGF receptor and MAPK signaling to avoid the AR pathway, resulting in delayed prostate cancer progression.